Novartis consolidates its presence in Italy and invests in R&D
( La Repubblica Affari & Finanza Pag.28 – 07/03/2011 )
Novartis consolidates its presence in Italy by increasing investments in R&D. According to the results of a study by Ce.Ri.S.Ma.S. (Center for Research and Studies in Health Management of the Catholic University of Milan) which analyzed in quantitative terms the contribution of the pharmaceutical sector to the production chain and national economy, Novartis contributes 0.1% to the national GDP, 0.2% in Lombardy and Tuscany and 0.3% for the Province of Trento. The overall impact of related industries on the Italian economy is over 2 billion euros. There are 14,966 jobs generated, of which almost 6,961 concern R&D, a sector to which Novartis allocated resources for 192 million euros in 2010.
Takeda invests a further 5 million in the Cerano (NO) plant
( La Repubblica Affari & Finanza Pag.28 – 07/03/2011 )
Takeda focuses on the production center of Cerano (NO), which also becomes the pivot for the distribution of Mepact (mifamurtide), a new medicine for osteosarcoma, which has obtained the recognition of orphan drug. Maurizio Castorina, Chief Executive Officer, explains: "To the 17 million euros already spent on machinery and expansions, we have added 5 million to enhance the production of candesartan against hypertension and lansoprazole for gastrointestinal disorders, as well as to improve packaging and control cycle of Mepact, produced in Japan and now available in Italy".
